ClinicalTrials.gg
CompletedNCT07816575Updated Sep 11, 2026

Comparative Efficacy of Alpha Hydroxy Acids With and Without Nanocarriers Versus Calcipotriol Plus Betamethasone in Treatment of Plaque Psoriasis

An interventional study of Alpha Hydroxy Acids with nanocarriers and Alpha Hydroxy Acids only. in Psoriasis, sponsored by Al-Azhar University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by Al-Azhar University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 5 months after the study started (first participant enrolled Mar 2024, registered Sep 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies in Psoriasis with a site in Egypt — 16 open to participants now, 16 under way, 2 of them phase 3. Psoriasis · Egypt.

Enrollment
6th of 43
80 · median 40
Started
2024
with 4 others
No phase
24 of 54
7 open now
Registered
51st of 54
by date
Lead sponsor
3 of 54
Al-Azhar University

Among the 54 studies in Psoriasis with a site in Egypt, this one is the 6th largest by enrollment of the 43 interventional ones that give a count, is one of 5 that started in 2024, is one of 24 with no phase, and was the 51st registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

16 of the 54 studies in Psoriasis with a site in Egypt are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Psoriasis with a site in Egypt, or all of them as a file.
02

Study summary

The aim of this double blind comparative clinical study is to evaluate the efficacy of AHAs combined with nanocarriers and their use as a non steroidal alternative drug for long term management of plaque psoriasis

03

Conditions studied

  • Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:- Mid to moderate cases according to Psoriasis Area and Severity Index (PASI).

  • Age from18-65 years old.
  • Denovo psoriatic patients and patients with no psoriasis therapy in the previous two months.

Exclusion Criteria:

  • Severe irritation and highly inflamed skin.
  • Pregnant and lactating females.
  • Patients with acute renal insufficiency.
  • Face, flexural and groin lesions.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Alpha Hydroxy Acids with Nanocarriers Group

    Patients received Alpha Hydroxy Acids formulated with nanocarriers.

    Drug: Alpha Hydroxy Acids with nanocarriers

  • Experimental
    Alpha Hydroxy Acids Group.

    Patients received Alpha Hydroxy Acids only.

    Drug: Alpha Hydroxy Acids only.

  • Active comparator
    Calcipotriol plus betamethasone Group.

    Patients received calcipotriol plus betamethasone.

    Drug: Calcipotriol plus betamethasone

  • Placebo comparator
    Placebo Group

    Patients received placebo comparator.

    Other: Placebo.

Interventions

  • DrugAlpha Hydroxy Acids with nanocarriers

    Topical Alpha Hydroxy Acids formulated with nanocarriers applied to psoriatic plaques.

  • DrugAlpha Hydroxy Acids only.

    Topical Alpha Hydroxy Acids only applied to psoriatic plaques.

  • DrugCalcipotriol plus betamethasone

    Drug pages: Calcipotriene · Betamethasone

    Topical calcipotriol plus betamethasone ointment applied to psoriatic plaques.

  • OtherPlacebo.

    Vehicle control / Placebo topical application applied to psoriatic plaques

06

What researchers measure

Primary outcomes

  1. Percentage Change in PASI Score.

    Reduction in PASI score from baseline to week 8.

    Time frame: Baseline and 8 weeks

Secondary outcomes

  1. Dermatology Life Quality Index (DLQI)

    Changes in DLQI score to assess the impact of treatment on patients' quality of life.

    Time frame: Baseline and 8 weeks).

Other outcomes

  1. Frequency of Adverse Events

    Assessment of any adverse effects related to the applied therapies.

    Time frame: Throughout the study period (up to 8 weeks)

07

Study locations

1 site
  • Al-Hussien and cairo dermatology Hospital
    Cairo, Egypt
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in Jul 2025, 15 months.

Of 115 non-industry interventional studies with no phase under Psoriasis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's 15 months is below that.

Counting every sponsor, half of 134 studies reached it within 19 months; a quarter within 8 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2026
First posted
Sep 11, 2026
StartActual
Mar 15, 2024
Primary completionActual
Jul 3, 2025
CompletionActual
Sep 10, 2025
Last update
Sep 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07816575
Responsible party
Bodour Kamal Elshenawy (Resident, Al-Azhar University) — Principal investigator
First posted
Sep 11, 2026
Start date
Mar 15, 2024
Primary completion
Jul 3, 2025
Completion
Sep 10, 2025
Last update
Sep 11, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion